{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:02:26Z","timestamp":1756339346716,"version":"3.44.0"},"reference-count":22,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["DTB"],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:p>Hyperkalaemia is a potentially life-threatening condition, in which there is an abnormally high concentration of potassium ions in the blood.<jats:sup>1,2<\/jats:sup> Cation-exchange resins (e.g. calcium or sodium polystyrene sulfonate) that bind potassium in the gastrointestinal tract to increase faecal elimination have been used as part of the management of hyperkalaemia but they have some serious adverse effects, including potentially fatal gastrointestinal necrosis.<jats:sup>3,4<\/jats:sup> Patiromer (\u25bcVeltassa \u2013 Vifor Fresenius) is a cation-exchange polymer that is licensed for the treatment of hyperkalaemia in adults and, unlike other exchange resins, its licence is not restricted to people with anuria, severe oliguria or those requiring or undergoing dialysis.<jats:sup>5,6<\/jats:sup> Here, we review the evidence for the efficacy and safety of patiromer and consider its place in the management of hyperkalaemia.<\/jats:p>","DOI":"10.1136\/dtb.2018.1.0575","type":"journal-article","created":{"date-parts":[[2018,1,11]],"date-time":"2018-01-11T19:10:28Z","timestamp":1515697828000},"page":"6-9","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["\u25bcPatiromer for the management of hyperkalaemia"],"prefix":"10.1136","volume":"56","member":"239","published-online":{"date-parts":[[2018,1,11]]},"reference":[{"key":"2025082623264644000_56.1.6.1","unstructured":"UK Renal Association, 2014. Clinical practice guidelines: treatment of acute hyperkalaemia in adults [online]. Available: https:\/\/renal.org\/wp-content\/uploads\/2017\/06\/hyperkalaemia-guideline-1.pdf [Accessed 13 December 2017]."},{"key":"2025082623264644000_56.1.6.2","unstructured":"Scottish Intercollegiate Guidelines Network, 2008. Diagnosis and management of chronic kidney disease (Sign 103) [online]. Available: http:\/\/www.sign.ac.uk\/sign-103-diagnosis-and-management-of-chronic-kidney-disease.html [Accessed 13 December 2017]."},{"key":"2025082623264644000_56.1.6.3","unstructured":"Calcium resonium 99.934% w\/w powder for oral\/rectal suspension. Summary of product characteristics, UK. Aventis Pharma Limited, January 2014."},{"key":"2025082623264644000_56.1.6.4","unstructured":"Resonium A . Summary of product characteristics, UK. Aventis Pharma Limited, January 2014."},{"key":"2025082623264644000_56.1.6.5","unstructured":"Veltassa (patiromer). Summary of product characteristics, UK. Vifor Fresenius Medical Care Renal Pharma UK Ltd, 2017."},{"key":"2025082623264644000_56.1.6.6","unstructured":"European Medicines Agency, 2017. Assessment report: Veltassa [online]. Available: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/004180\/WC500232691.pdf [Accessed 13 December 2017]."},{"key":"2025082623264644000_56.1.6.7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h4762"},{"key":"2025082623264644000_56.1.6.8","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1152\/advan.00121.2016","article-title":"Physiology and pathophysiology of potassiumhomeostasis","volume":"40","author":"Palmer","year":"2016","journal-title":"Adv PhysiolEduc"},{"key":"2025082623264644000_56.1.6.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.resuscitation.2015.07.017"},{"key":"2025082623264644000_56.1.6.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2012.06.037"},{"key":"2025082623264644000_56.1.6.11","unstructured":"National Kidney Foundation, 2016. Hyperkalemia in chronic kidney disease [online]. Available: https:\/\/www.kidney.org\/sites\/default\/files\/02-10-7259%20Hyperkalemia%20Tool.pdf [Accessed 13 December 2017]."},{"key":"2025082623264644000_56.1.6.12","first-page":"55","article-title":"New agents in treatment of hyperkalemia: an opportunity to optimize use of RAAS inhibitors for blood pressure control and organ protection in patients with chronic kidney disease","volume":"18","author":"Rastogi","year":"2016","journal-title":"CurrHypertens Rep"},{"key":"2025082623264644000_56.1.6.13","unstructured":"National Institute for Health and Care Excellence, 2014. Chronic kidney disease in adults: assessment and management (CG 182) [online]. Available: https:\/\/www.nice.org.uk\/guidance\/cg182 [Accessed 13 December 2017]."},{"key":"2025082623264644000_56.1.6.14","unstructured":"Scottish Intercollegiate Guidelines Network, 2016. Management of chronic heart failure (Sign 147) [online]. Available: http:\/\/www.sign.ac.uk\/assets\/sign147.pdf [Accessed 13 December 2017]."},{"key":"2025082623264644000_56.1.6.15","doi-asserted-by":"publisher","DOI":"10.1177\/1060028016640794"},{"key":"2025082623264644000_56.1.6.16","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1358\/dot.2015.51.12.2420391","article-title":"Patiromer: a significant advance in the management of hyperkalemia","volume":"51","author":"Paton","year":"2015","journal-title":"Drugs Today"},{"key":"2025082623264644000_56.1.6.17","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.7446"},{"key":"2025082623264644000_56.1.6.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1410853"},{"key":"2025082623264644000_56.1.6.19","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.402"},{"key":"2025082623264644000_56.1.6.20","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s40261-016-0432-9","article-title":"Patiromer: a review in hyperkalaemia","volume":"36","author":"Kim","year":"2016","journal-title":"Clin Drug Investig"},{"key":"2025082623264644000_56.1.6.21","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1177\/1074248417691135","article-title":"Evaluation of the potential for drug interactions with patiromer in healthy volunteers","volume":"22","author":"Lesko","year":"2017","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"2025082623264644000_56.1.6.22","unstructured":"Guidelines and Audit Implementation Network (GAIN), 2014. Guidelines for the treatment of hyperkalaemia in adults [online]. Available: https:\/\/www.rqia.org.uk\/RQIA\/files\/6f\/6f51b366-f8bf-44de-a630-6967d5353a87.pdf [Accessed 13 December 2017]."}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.2018.1.0575","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T06:26:55Z","timestamp":1756276015000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.2018.1.0575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,1,11]]},"published-print":{"date-parts":[[2018,1]]}},"alternative-id":["10.1136\/dtb.2018.1.0575"],"URL":"https:\/\/doi.org\/10.1136\/dtb.2018.1.0575","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"type":"print","value":"0012-6543"},{"type":"electronic","value":"1755-5248"}],"subject":[],"published":{"date-parts":[[2018,1]]}}}